Articles

Researchers are beginning to explore how GLP-1 therapies may influence sleep, recovery, and overall metabolic health. Could a medication designed for blood sugar control also help patients sleep better? As surprising as it sounds, emerging evidence suggests a meaningful connection. This article looks at how GLP-1 receptor agonists may indirectly …

Many patients describe a surprising shift when starting GLP-1 therapies: cravings feel quieter, and the constant pull toward food seems to fade. This experience, often called “food noise,” reflects deeper biological changes driven by GLP-1–based appetite signaling in the body. But what exactly is happening in the brain, and how …

When managing type 2 diabetes, most people focus on blood sugar. However, what if one medication could also improve heart health at the same time? That is exactly what researchers are discovering about how GLP-1 drugs affect blood pressure. These medications, originally designed to control glucose, are now showing consistent …

Type 2 diabetes management has evolved rapidly over the past decade. As new therapies improve glucose control and cardiometabolic outcomes, many patients achieve better metabolic stability than before. However, this progress often comes with a challenge: medication overload. Deprescribing in diabetes care has emerged as a thoughtful clinical approach that …

Continuous ketone monitoring for diabetes is emerging as one of the most intriguing developments in metabolic care. For decades, clinicians relied on periodic blood or urine tests to detect rising ketones. However, those methods often identify problems only after metabolic imbalance has already progressed. In contrast, newer sensor systems promise …

The concept of CKM staging in primary care has gained attention as clinicians look for better ways to manage the growing overlap between cardiovascular disease, kidney disease, diabetes, and metabolic disorders. However, many providers still wonder how to translate the CKM framework into daily clinical practice. Think of CKM staging …

GLP-1 receptor agonists have reshaped the management of type 2 diabetes and obesity. However, growing interest now surrounds the potential role of GLP-1 therapy in normal-weight patients with cardiometabolic risk and whether treatment decisions should rely less on BMI alone. While body mass index remains a widely used screening tool, …

GLP-1 receptor agonists have transformed diabetes care, but the long-term safety of GLP-1 therapies has become an important topic as treatment continues for many years. Initially, clinicians prescribed these medications primarily for glycemic control in patients with type 2 diabetes. However, their role has expanded due to additional benefits in …

Chronic kidney disease (CKD) remains one of the most serious complications associated with diabetes, affecting millions of patients worldwide. While SGLT2 inhibitors have become foundational therapies for protecting kidney function, researchers are increasingly examining whether other drug classes may also slow renal decline. In particular, growing interest surrounds how GLP-1 …

GLP-1 receptor agonists have transformed diabetes and obesity treatment, yet safety questions still surface in clinic visits. One concern continues to appear in patient discussions: thyroid cancer risk. The topic often traces back to early rodent studies that triggered boxed warnings for medullary thyroid carcinoma (MTC). However, clinicians today rely …